Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-04-25

FDA Approved: IRBESARTAN AND HYDROCHLOROTHIAZIDE — Supplemental Application (Alembic Pharmaceuticals Limited)

View source ↗

Summary

FDA approved a supplemental application for IRBESARTAN AND HYDROCHLOROTHIAZIDE, a generic fixed‑dose combination by Alembic Pharmaceuticals Limited.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • IRBESARTAN AND HYDROCHLOROTHIAZIDE (irbesartan and hydrochlorothiazide)

Snippet

SUPPL AP for IRBESARTAN AND HYDROCHLOROTHIAZIDE (IRBESARTAN AND HYDROCHLOROTHIAZIDE)